Eric Jonasch MD

Dr. Eric Jonasch is a Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Center at the University of Texas M. D. Anderson Cancer Center in Houston, Texas. He held his clinical residency in internal medicine at the Royal Victoria Hospital in Montreal, Canada, his clinical fellowship in hematology/oncology at the New England Medical Center in Boston, Massachusetts, and his research fellowship at the Beth Israel Deaconess Medical Center in Boston, Massachusetts. He was on faculty at the Massachusetts General Hospital for three years before moving to MD Anderson Cancer Center in Houston.

Dr. Jonasch is the director of the VHL Clinical Center at the MD Anderson Cancer Center and is involved in tissue-based translational research in renal cell carcinoma and VHL disease. He heads a number of investigator-initiated clinical trials and is the PI of the Department of Defense Kidney Cancer Research Consortium.

Dr. Jonasch is in charge of an ongoing laboratory research effort evaluating the determinants of response and resistance to therapy in renal cell carcinoma and VHL disease.   Dr. Jonasch’s current work focuses on understanding the drivers of renal cell carcinoma tumor ontogeny, and the development of informative models of tumor-microenvironmental interaction.

Dr. Jonasch is the author or co-author of over 250 articles published in peer-reviewed journals, and numerous book chapters, and editor of a textbook: Kidney Cancer, Principles and Practice. Dr. Jonasch is a journal reviewer for the New England Journal of Medicine, the Journal of Clinical Oncology, and the Journal of Clinical Investigation, and Cancer Research.

Dr. Jonasch is a member of multiple professional organizations, including, but not limited to the American Association for Cancer Research and the American Association of Cancer Research. Dr. Jonasch serves as Vice-Chair of the NCCN Kidney Cancer Guideline Panel and is a Board member of the International Kidney Cancer Coalition.